|
The results of the breakthrough clinical trial have been described
in a peer reviewed journal, Cutis. The abstract appears below.
Casanova G, Cancela R, Alonzo L, Benuto R, del Carmen Magana M,
Hurley DP, Fishbein E, Lara C, Gonzalez T, Ponce R, Burnett JW,
Calton GJ. A double-blind study of the efficacy and safety of the
ICP10)PK vaccine against recurrent genital HSV-2 infections. Cutis.
2002;70(4):235-239.
A randomized double-blind trial to evaluate the safety of a novel
recombinant virus, ICP10)PK, for reduction or prevention of recurrent
herpes simplex virus type 2 (HSV-2) infection was carried out in
public hospitals in Mexico City. Persons having a minimum of 5 documented
herpetic recurrences in the previous year were randomized for vaccination.
Patients were examined within 72 hours of lesion occurrence. If
accepted into the study, the patient was inoculated subcutaneously
in the upper deltoid muscle area at days 7, 17, and 28 after initiation
of lesion occurrence. Recurrences were recorded by patient diary
and physician examination.
continue
|